Comparison of follicular T helper cells, monocytes, and T cells priming between newly diagnosed and rituximab-treated MS patients and healthy controls

BACKGROUND AND PURPOSE: The use of anti-CD20 monoclonal antibodies like rituximab (RTX) to deplete B cells has practical therapeutic implications in multiple sclerosis (MS) patients. However, the therapy’s impact on other immune cells is also important. Therefore, in this study, we assessed the effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yahyazadeh, Sheida, Esmaeil, Nafiseh, Shaygannejad, Vahid, Mirmosayyeb, Omid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075021/
https://www.ncbi.nlm.nih.gov/pubmed/35531136
http://dx.doi.org/10.4103/1735-5362.343085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075021/
https://www.ncbi.nlm.nih.gov/pubmed/35531136
http://dx.doi.org/10.4103/1735-5362.343085

Ejemplares similares